TELA Bio, Inc. Common Stock

Day range

$0.96 – $1.06

Open

$0.96

Prev close

$0.97

Volume

97.21K

Market cap

$43.56M

Shares out

45.14M

P/E

—

P/S

0.55

P/B

-2.76

P/FCF

—

ROE

259.5%

ROA

-68.9%

Debt/Equity

-3.53

Div yield

0.00%

As of Oct 23, 2026

• Listing compliance regainedOct 8, 2026

  On October 5, 2026, the Company received a letter from The Nasdaq Stock Market LLC stating that the Company has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Market under Nasdaq Listing Rule 5450(a)(1). As a result, the Company does not intend to effect the reverse stock split at this time.

• Listing compliance regainedOct 6, 2026

  On October 5, 2026, TELA Bio, Inc. (the "Company") received a letter from The Nasdaq Stock Market LLC stating that the Company has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Market under Nasdaq Listing Rule 5450(a)(1) and the matter is now closed.

• Regulatory decisionOct 5, 2026

  On October 5, 2026, TELA Bio, Inc. issued a press release announcing that it has received U.S. Food and Drug Administration 510(k) clearance for its Liora Monofilament Scaffold product.

• Credit facilitySep 29, 2026

  On September 28, 2026, TELA Bio, Inc. entered into a Limited Consent to Credit Agreement and Guaranty with Perceptive Credit Holdings V, LP, as administrative agent and collateral agent, and the lenders party thereto constituting the Required Lenders.

• Listing deficiency noticeSep 18, 2026

  The Staff notified the Company by letter dated September 15, 2026, that the Company's listed security is subject to delisting from Nasdaq unless the Company timely requests a hearing before a Nasdaq Hearings Panel. The notice followed the Company's failure to regain compliance with Nasdaq's $1.00 minimum bid price requirement within the 180-calendar-day grace period.

Days to cover

1.8

Short interest

469.15K

Avg volume

261.82K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• TELA Bio Announces 510(k) Clearance for Liora™ Monofilament Scaffold for Soft Tissue Reinforcement
  positiveGlobeNewswire Inc.· Oct 5, 2026
• TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  neutralGlobeNewswire Inc.· Feb 20, 2026
• Hernia Repair Devices Market is Set to Attain Valuation of US$ 6.57 Billion by 2033 | Astute Analytica
  positiveGlobeNewswire Inc.· Jun 25, 2025
• TELA Bio Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares
  positiveBenzinga· Oct 24, 2024
• TELA Bio Appoints Jeffrey Blizard to its Board of Directors
  GlobeNewswire Inc.· Jun 4, 2024